Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$196.82 USD

196.82
2,946,862

-0.14 (-0.07%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat

Although Gilead Sciences (GILD) topped estimates in the third quarter, weak HCV sales has dampened investors sentiment.

    AbbVie (ABBV) Q3 Earnings Surpass Estimates, Guidance Raised

    AbbVie's third-quarter 2017 earnings surpassed estimates with revenue in line with the same. Sales of its??? lead marketed drug Humira also increased compared to year ago figure.

      Tracey Ryniec headshot

      Must-Watch Earnings Charts to End the Week

      In this busy earnings week, a few stocks stand out from the pack. Be sure to tune into these earnings reports.

        Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View

        Vertex Pharma (VRTX) third-quarter earnings increased from the year-ago period led by strong sales of CF drugs.

          Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus

          Bristol-Myers (BMY) Q3 earnings miss estimates while revenues beat the same. Opdivo's label was expanded to two more indications.

            Key Predictions for Q3 Earnings Reports of ABBV, MRK

            The third quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players AbbVie and Merck follow suit.

              Arpita Dutt headshot

              Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod

              Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.

                Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up

                Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.

                  Can AbbVie (ABBV) Spring a Surprise this Earnings Season?

                  Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.

                    Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength

                    Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.

                      Sweta Killa headshot

                      Healthcare ETFs Set to Soar as Q3 Earnings Unfold

                      With earnings surprises well in the cards, healthcare ETFs are set to soar.

                        Is Gilead (GILD) Poised for a Beat This Earnings Season?

                        A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.

                          Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics

                          AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.

                            Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

                            Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

                              What's in the Cards for Novartis (NVS) This Earnings Season?

                              Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.

                                Tracey Ryniec headshot

                                Where to Find Value in Healthcare Stocks

                                The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.

                                  Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

                                  Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

                                    J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

                                    J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

                                      The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

                                      The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

                                        J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use

                                        Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.

                                          Cancer Space Update: Lung & Breast Cancer Studies in Focus

                                          While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

                                            Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock?

                                            Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

                                              Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA

                                              Allergan plc (AGN) announced that the FDA has accepted the new drug application (NDA) for ulipristal acetate, for the treatment of abnormal uterine bleeding in women with uterine fibroids.

                                                Arpita Dutt headshot

                                                Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

                                                With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

                                                  Here's What's Has Happened in the HCV Space Lately

                                                  A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.